Precigen, Inc. - Common Stock (PGEN)

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Precigen's Q3 2025 results show a huge revenue beat but a wider-than-expected loss. The key highlight is the full FDA approval and launch of its new therapy, PAPZIMEOS.

Precigen (PGEN) Q3 2025 Earnings Call Transcript

Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares

Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July.

Discover the stocks with unexpected trading volume in today's session on the US markets.

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.

Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.

The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.